Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ-100 in Pediatric CNS Tumors
NCT02462629Phase 1Completed
- Sponsor
- Blaze Bioscience
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tozuleristide in central nervous system tumor, sponsored by Blaze Bioscience. Primary endpoints: Number of participants with adverse events and Change in concentration of BLZ-100 in the blood. Started Jun 2015; status: completed.
02
Drugs
tozuleristide
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT02462629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462629.